CF
ABBV icon

Centaurus Financial’s AbbVie ABBV Stock Holding History

Centaurus Financial’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.94M Sell
13,531
-24
-0.2% -$5.32K 0.14% 150
2025
Q4 		$3.1M Buy
13,555
+237
+2% +$54K 0.14% 149
2025
Q3 		$3.08M Buy
13,318
+4,821
+57% +$982K 0.14% 145
2025
Q2 		$1.58M Sell
8,497
-134
-2% -$24.9K 0.09% 217
2025
Q1 		$1.81M Buy
8,631
+124
+1% +$24.1K 0.11% 180
2024
Q4 		$1.51M Buy
8,507
+188
+2% +$34.6K 0.09% 206
2024
Q3 		$1.64M Buy
8,319
+1,199
+17% +$224K 0.1% 183
2024
Q2 		$1.22M Sell
7,120
-215
-3% -$35.6K 0.08% 217
2024
Q1 		$1.34M Sell
7,335
-301
-4% -$51.9K 0.09% 196
2023
Q4 		$1.18M Sell
7,636
-863
-10% -$126K 0.09% 215
2023
Q3 		$1.27M Buy
8,499
+399
+5% +$58.6K 0.11% 186
2023
Q2 		$1.09M Sell
8,100
-6,404
-44% -$939K 0.1% 218
2023
Q1 		$2.31M Buy
14,504
+941
+7% +$144K 0.19% 131
2022
Q4 		$2.19M Sell
13,563
-876
-6% -$134K 0.21% 126
2022
Q3 		$1.94M Buy
14,439
+667
+5% +$95.7K 0.19% 141
2022
Q2 		$2.11M Sell
13,772
-3,852
-22% -$589K 0.21% 128
2022
Q1 		$2.86M Sell
17,624
-68
-0.4% -$9.88K 0.23% 115
2021
Q4 		$2.4M Buy
17,692
+2,174
+14% +$257K 0.18% 148
2021
Q3 		$1.67M Buy
15,518
+118
+0.8% +$13.5K 0.14% 180
2021
Q2 		$1.74M Buy
15,400
+3,082
+25% +$347K 0.15% 172
2021
Q1 		$1.33M Buy
12,318
+3,769
+44% +$403K 0.13% 188
2020
Q4 		$916K Sell
8,549
-710
-8% -$68.2K 0.1% 248
2020
Q3 		$811K Sell
9,259
-1,170
-11% -$110K 0.11% 202
2020
Q2 		$1.02M Buy
10,429
+2,201
+27% +$194K 0.15% 168
2020
Q1 		$627K Buy
8,228
+4,058
+97% +$346K 0.13% 188
2019
Q4 		$369K Buy
+4,170
New +$346K 0.05% 353
2018
Q4 		– Sell
-1
Closed -$105 – 468
2018
Q3 		$105 Sell
1
-13,745
-100% -$1.3M 0.02% 514
2018
Q2 		$1.27M Buy
13,746
+12,130
+751% +$1.18M 0.18% 126
2018
Q1 		$153K Buy
+1,616
New +$178K 0.04% 365

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Centaurus Financial's ABBV Position: Q1 2026 in Review

Centaurus Financial reduced its AbbVie (ABBV) stake by 0.18% in Q1 2026, selling an estimated $5.32K and leaving 13,531 shares worth $2.94M. The position accounts for 0.14% of the portfolio, ranked #150.

Centaurus Financial first reported a position in ABBV in Q1 2018 and has held it in 29 quarters since. The position peaked at $3.1M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Centaurus Financial held 13,531 shares of AbbVie worth $2.94M as of Q1 2026.
  • Centaurus Financial sold 24 AbbVie shares in Q1 2026, an estimated $5.32K.
  • AbbVie made up 0.14% of Centaurus Financial's portfolio in Q1 2026, its #150 holding.
  • Centaurus Financial first reported a position in AbbVie in Q1 2018 and has held it in 29 quarters since.
  • Centaurus Financial's AbbVie position peaked at $3.1M in Q4 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Centaurus Financial's 13F filing for Q1 2026, filed 18 May 2026.